- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06694701
Traitement par l'emapalumab pour le bénéfice clinique attendu en cas de sepsis grâce à l'endotype interféron-gamma (essai EMBRACE) (EMBRACE)
EMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of IFNγ-driven sepsis) endotype. EMBRACE also aims to identify the best dosing regimen of emapalumab for the management of IDS.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The EMBRACE trial aims to generate proof-of-concept if treatment with emapalumab, a monoclonal antibody which blocks IFNγ signaling, may improve the outcome of patients with sepsis driven by the IDS endotype. In EMBRACE, two different dose regimens of emapalumab are administered in order to: a) investigate which dose regimen may provide most of efficacy in the decrease of SOFA score, a new endpoint for sepsis suggested already by others; b) investigate which dose regimen better attains the pharmacodynamic goal of emapalumab defined as the decrease of blood CXCL9; and c) compare the efficacy of the two dose regimens with placebo treated patients.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Alexandroupoli, Grèce
- Intensive Care Unit, Alexandroupolis University General Hospital
-
Athens, Grèce
- 4th Department of Internal Medicine, ATTIKON University General Hospital
-
Athens, Grèce
- Intensive Care Unit, Korgialeneio-Benakeio HRC Athens General Hospital
-
Athens, Grèce
- 3rd University Department of Internal Medicine, Sotiria Chest Diseases Athens General Hospital
-
Athens, Grèce
- Intensive Care Unit I, KAT Attica General Hospital
-
Athens, Grèce
- Intensive Care Unit of 1st University Department Respiratory Medicine, Sotiria Chest Diseases Athens General Hospital
-
Athens, Grèce
- Intensive Care Unit of Center for Respiratory Failure, Sotiria Chest Diseases Athens General Hospital
-
Athens, Grèce
- Intensive Care Unit, Asklipieio Voulas General Hospital
-
Athens, Grèce
- Intensive Care Unit, Ippokrateio Athens General Hospital
-
Athens, Grèce
- Intensive Care Unit, Laiko Athens General Hospital
-
Athens, Grèce
- New Multivalent Intensive Care Unit, Sotiria Chest Diseases Athens General Hospital
-
Athens, Grèce
- Ηigh Dependency Unit of Department of Clinical Therapeutics, Alexandra Athens General Hospital
-
Pátrai, Grèce
- Intensive Care Unit, Patras University General Hospital
-
Thessaloniki, Grèce
- 1st Intensive Care Unit, G. Papanikolaou Thessaloniki General Hospital
-
Thessaloniki, Grèce
- Department of Anesthesiology and Intensive Care, AHEPA Thessaloniki University General Hospital
-
Thessaloniki, Grèce
- Intensive Care Unit, 424 General Military Training Hospital
-
Thessaloniki, Grèce
- Intensive Care Unit, Aghios Dimitrios Thessaloniki General Hospital
-
Thessaloniki, Grèce
- Intensive Care Unit, G. Gennimatas Thessaloniki General Hospital
-
Thessaloniki, Grèce
- Intensive Care Unit, Ippokrateio Thessaloniki General Hospital
-
Thessaloniki, Grèce
- Intensive Care Unit, Papageorgiou Thessaloniki General Hospital
-
Thessaloniki, Grèce
- Intensive Care Unit, Theageneio Thessaloniki Cancer Hospital
-
-
Attica
-
Elefsina, Attica, Grèce
- 1st Department of Internal Medicine, Thriasio Elefsis General Hospital
-
Kifissia, Attica, Grèce
- Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital
-
-
Crete
-
Heraklion, Crete, Grèce
- Intensive Care Unit, University General Hospital of Heraklion
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Provide written informed consent
- Adults (≥18 years) of male or female sex
- Diagnosis of community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), intrabdominal infection (IAI), acute pyelonephritis (AP), primary bloodstream infection (BSI) and viral respiratory infections.
- Sepsis defined by the Sepsis-3 definitions. This is defined as any new infection which is accompanied by an increase of the total baseline SOFA score by at least 2 points. The total baseline SOFA score is calculated by the medical comorbidities and by the evaluation of clinical variables before the sepsis episode in the case of hospital-acquired sepsis. In the case of patients with unknown baseline SOFA score, sepsis is defined as any new infection accompanied by total SOFA score 2 or more.
- Willingness to use effective contraceptive methods during the period from the start of the study drug to 6 months after the administration of the last dose of the study drug, in patients of reproductive age.
- Serological documentation of IDS defined as detectable blood IFNγ and CXCL9 more than 2,200 pg/ml. IFNγ and CXCL9 are measured in the central study lab by an enzyme immunosorbent assay.
- Absence of sepsis-induced immunoparalysis (SII). This is defined as ≥8000 of HLA-DR receptors on CD45/CD14-monocytes measured by flow-cytometry in the central lab using the BD™ fluorescence assay9.
Exclusion Criteria:
- Body weight more than 104 kg
- Intake of any other biological during the last 30 days prior screening except for the intake of anakinra or tocilizumab for patients with active infection by SARS-CoV-2
- Intake of any Janus kinase inhibitors during the last 30 days prior screening except for the intake of baricitinib for patients with active infection by SARS-CoV-2
- Known active infection by Mycobacterium tuberculosis or other mycobacteria. These patients may be enrolled in the trial if treatment against infection by Mycobacterium tuberculosis or other mycobacteria has been initiated
- Known active infection by VZV (varicella zoster virus) or by Histoplasma capsulatum or by Leishmania spp. These patients may be enrolled in the trial if treatment against infection by VZV or Histoplasma capsulatum has been initiated
- Known active infection by the hepatitis B virus, by the hepatitis C virus and by cytomegalovirus
- Vaccination the last 12 weeks before screening with BCG vaccine
- Vaccination with any live or attenuated live vaccine (other than BCG) the last 12 weeks before screening
- Known allergy or hypersensitivity reactions to emapalumab
- Patients living with the human immunodeficiency virus (HIV)
- Patients with stage IV solid or hematologic malignancy
- Patients with neutropenia (less than 1,000 neutrophils/mm3)
- Patients transplanted for solid organ or stem cells
- Pregnancy or lactation
- Participation in any other interventional trial the last 28 days prior to day 1
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
Standard-of-care (SoC) treatment and placebo drug. |
250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply |
|
Comparateur actif: Emapalumab Group 1
SoC treatment and a low dose of emapalumab. |
The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Autres noms:
The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Autres noms:
|
|
Comparateur actif: Emapalumab Group 2
SoC treatment and a high dose of emapalumab. |
The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Autres noms:
The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Decrease of SOFA score by the end-of-treatment
Délai: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
The study primary endpoint is the decrease of SOFA score by the end-of-treatment (EOT). This is defined as either a) at least 1.4 points decrease of mean SOFA score calculated between days 1 and EOT from SOFA score of day 0; OR b) at least 2 points decrease of SOFA at EOT from day 0. |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Le nombre de doses requises dans chaque groupe pour obtenir la réponse du score SOFA par l'EOT.
Délai: De l'inscription à la fin du traitement du médicament à l'étude pour chacun des participants à l'étude, allant de 2 à 29 jours.
|
De l'inscription à la fin du traitement du médicament à l'étude pour chacun des participants à l'étude, allant de 2 à 29 jours.
|
|
|
Mortalité à 28 jours
Délai: De l'inscription jusqu'à 28 jours après l'inscription.
|
De l'inscription jusqu'à 28 jours après l'inscription.
|
|
|
The rate of serious TEAEs and non-serious TEAEs
Délai: From enrollment to the end of observation of each of the study participants, which is 120 days plus or minus 3 days, after each participant's enrollment.
|
Comparison of the rate of serious TEAEs and non-serious TEAEs between the three groups of treatment. |
From enrollment to the end of observation of each of the study participants, which is 120 days plus or minus 3 days, after each participant's enrollment.
|
|
The change of the SOFA score from day 0 until day 7
Délai: From enrollment (day 0) to 8 days after enrollment (day 7).
|
Comparison of the change of the SOFA score from day 0 until day 7 |
From enrollment (day 0) to 8 days after enrollment (day 7).
|
|
The change of the SOFA score from 0 until day 28
Délai: From enrollment to 28 days after enrollment.
|
Comparison of the change of the SOFA score from 0 until day 28 |
From enrollment to 28 days after enrollment.
|
|
The change of the SOFA score from 0 until EOT
Délai: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the change of the SOFA score from 0 until EOT |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The pharmacokinetics of emapalumab
Délai: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the pharmacokinetics of emapalumab |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The need to stop the study drug due to drop of the number of HLA-DR receptors on CD14-monocytes.
Délai: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the need to stop the study drug due to drop of the number of HLA-DR receptors on CD14-monocytes. |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The circulating concentrations of IL-6, ferritin, IFNγ and CXCL9 over the days of treatment
Délai: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the circulating concentrations of IL-6, ferritin, IFNγ and CXCL9 over the days of treatment |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Autres mesures de résultats
Mesure des résultats |
Délai |
|---|---|
|
Comparaison entre les trois groupes de traitement pour le profil protéomique par rapport au traitement
Délai: De l'inscription à la fin du traitement du médicament à l'étude pour chacun des participants à l'étude, allant de 2 à 29 jours.
|
De l'inscription à la fin du traitement du médicament à l'étude pour chacun des participants à l'étude, allant de 2 à 29 jours.
|
|
Les comparaisons entre les trois groupes de traitement pour l'évolution du profil transcriptomique au cours du traitement
Délai: De l'inscription à la fin du traitement du médicament à l'étude pour chacun des participants à l'étude, allant de 2 à 29 jours.
|
De l'inscription à la fin du traitement du médicament à l'étude pour chacun des participants à l'étude, allant de 2 à 29 jours.
|
|
Les performances diagnostiques du SepsisLoop au point d'intervention pour SII par rapport au nombre absolu de récepteurs HLA-DR sur les monocytes CD45/CD14.
Délai: De l'inscription à la fin du traitement du médicament à l'étude pour chacun des participants à l'étude, allant de 2 à 29 jours.
|
De l'inscription à la fin du traitement du médicament à l'étude pour chacun des participants à l'étude, allant de 2 à 29 jours.
|
|
Les données cliniques et les niveaux de biomarqueurs au chevet lors du dépistage pour le développement potentiel d'un outil de diagnostic classant la population étudiée en IDS
Délai: De l'inscription à la fin du traitement du médicament à l'étude pour chacun des participants à l'étude, allant de 2 à 29 jours.
|
De l'inscription à la fin du traitement du médicament à l'étude pour chacun des participants à l'étude, allant de 2 à 29 jours.
|
|
Les niveaux de biomarqueurs pronostiques lors du dépistage classant la population Sepsis en différents sous-groupes
Délai: De l'inscription à la fin du traitement du médicament à l'étude pour chacun des participants à l'étude, allant de 2 à 29 jours.
|
De l'inscription à la fin du traitement du médicament à l'étude pour chacun des participants à l'étude, allant de 2 à 29 jours.
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chaise d'étude: Evangelos Giamarellos-Bourboulis, Hellenic Institute for the Studies of Sepsis
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- EMBRACE
- 2024-515255-38-00 (Ctis)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .